MindMed’s Bet on Psychedelic Psychiatry: Vanguards of Health Care https://www.bloomberg.com/news/audi...nguards-of-health-care?srnd=homepage-americas
Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) https://finance.yahoo.com/news/institutional-investors-own-significant-stake-123730402.html
Secretary of VA Collins mentioned yesterday in the 100 day cabinet meeting that evaluating psychedelic treatment for vets is a main focus. A lot of eyes were on this meeting. https://www.11alive.com/article/new...ments/85-d90e6b9d-a705-4f09-aeda-5b839879bd03 https://x.com/RepDougCollins/status/1916865789707116975
MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates https://ir.mindmed.co/news-events/p...financial-results-and-recent-business-updates
Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance https://insights.citeline.com/in-vi...delic-renaissance-J5TLUOIOIJFUHPWMQS2PRGYPOE/
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors https://www.benzinga.com/markets/ca...t-means-for-investors?utm_source=articleShare
MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer May 27, 2025 7:00 am EDT MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer :: Mind Medicine (MindMed) Inc. (MNMD) NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed’s executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527191230/en/ Brandi Roberts, CPA, Chief Financial Officer of MindMed “Brandi joins MindMed at a pivotal moment for the company, bringing with her a powerful combination of financial acumen, strategic vision, and deep biotech sector expertise,” said Rob Barrow, Chief Executive Officer of MindMed. “Her proven track record leading public companies through transformative milestones, including initial public offerings (IPO), business development and investor engagement makes her a valuable addition to our organization. As we accelerate toward the potential commercialization of MM120 ODT, her understanding of the healthcare landscape and executional strength will be instrumental in advancing our strategy, driving growth, and delivering long-term value for both patients and shareholders.” “MindMed is leading a true paradigm shift in mental health treatment, and I’m excited to collaborate with a team renowned for its exceptional depth and breadth of experience in drug development,” said Ms. Roberts. “With MM120 ODT, the company is advancing a potential breakthrough for the millions of people in the U.S. suffering from GAD and MDD. Joining MindMed is an extraordinary opportunity to continue building a robust financial infrastructure that matches the strength of the Company’s science; delivering a comprehensive strategic financial vision built to support innovation, agility, and access with the goal of helping patients and making a meaningful impact in addressing the mental health crisis.” Ms. Roberts has more than 25 years of financial leadership experience within the life sciences industry. Most recently, she served as CFO and Executive Vice President of Longboard Pharmaceuticals, where she helped lead the company through its IPO, multiple financings, and ultimately, its $2.6 billion acquisition by Lundbeck in 2024. Throughout her career, Ms. Roberts has played pivotal roles in scaling operations, supporting clinical development, and managing investor relations with leading investors, funds, and analysts. She has held CFO roles at Lineage Cell Therapeutics, REVA Medical, and Mast Therapeutics, and senior finance positions at Alphatec Spine, Inc., Artes Medical, Inc., Stratagene Corporation, and Pfizer, Inc. Ms. Roberts received her MBA from the University of San Diego and her B.S. degree in business administration in Accounting and Finance from the University of Arizona. She is a Certified Public Accountant in the State of California and currently serves on the board of advisors for Life Science Cares San Diego and the board for the Association of Bioscience Financial Officers Southwest chapter. Inducement Grants under Nasdaq Listing Rule 5635(c)(4) In connection with her appointment as Chief Financial Officer on June 2, 2025, MindMed will grant Ms. Roberts on such date inducement awards consisting of (i) an option to purchase 500,000 common shares of the Company (the "Option") and (ii) 125,000 performance share units (the “PSUs”) (assuming achievement at target levels of performance) that, if earned, will be settled in MindMed common shares upon vesting. The Option will have an exercise price equal to the closing price of MindMed’s common shares on May 30, 2025, the last trading day on which MindMed’s common shares will trade prior to the date of the grant and will vest over a four-year period with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the three-year period thereafter, subject to her continued employment. The PSUs will vest on the third anniversary of the grant date, subject to continued service through the vesting date. Actual earned PSUs can range from 0%-200% of the target number of PSUs and will be based on the achievement of certain performance metrics as measured at the end of the three-year performance period. The inducement awards to Ms. Roberts will be granted as a material inducement to her entering into employment with MindMed and were approved by MindMed's Compensation Committee on May 21, 2025, in accordance with Rule 5635(c)(4) of The NASDAQ Stock Market LLC. The awards were granted outside MindMed's equity incentive plans. About MindMed MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
Trump administration exploring potential benefits of psychedelic treatments Fox News correspondent Alexandria Hoff discusses the Trump administration’s stances on psychedelic treatments on ‘America’s Newsroom.’ Trump administration exploring potential benefits of psychedelic treatments | Fox News Video
https://www.linkedin.com/posts/mind...licmedicine-activity-7340033201014235136-HXgD Psychedelics are in the final stages of clinical development that could potentially allow for regulatory approval. Are you ready for it? Our CMO Dan Karlin is joining an incredible panel at Biotechnology Innovation Organization’s hashtag#BIO2025 to talk about the future of novel therapies for anxiety and depressive disorders, and more. This isn’t just a moment—it’s a movement. We’re forging a new era of psychiatry where novel therapeutics, guided by scientific rigor, can deliver accessible treatments and unlock healing at scale. If you’re attending BIO, stop by room #251 on June 16 at 1:45pm to hear what patients, providers, and payers need to know as this space evolves. Learn more here: https://lnkd.in/eAWKkBba hashtag#BrainHealth hashtag#PsychedelicMedicine hashtag#BIO2025
Psychedelics Are Driving a Mental Health Revolution with Long-Lasting Therapeutic Potential https://www.geneonline.com/psychede...tion-with-long-lasting-therapeutic-potential/ Good read featuring Blue Cross Blue Shield and Mindmed at BIO International Convention 2025
$MNMD New study shows LSD changes brain connectivity in unique ways compared to MDMA and amphetamines https://www.msn.com/en-us/health/ot...nd-amphetamines/ar-AA1BMFed?ocid=BingNewsVerp "LSD was the only substance to significantly reduce integrity in the default mode network—a brain system associated with self-reflection and daydreaming—which may help explain why LSD often produces a sense of ego dissolution. By contrast, MDMA and d-amphetamine did not significantly affect this network. In fact, LSD stood out in nearly every measure of between-network connectivity, increasing communication between brain networks more extensively than either amphetamine." Link to full study: https://www.nature.com/articles/s41380-024-02734-y LSD for the win...
"To qualify for the expedited review program, companies must submit the chemistry, manufacturing, and controls (CMC) portion of the application at least 60 days before submitting the final application. Companies must also be available for ongoing communication with the agency." FDA to Issue New Commissioner’s National Priority Vouchers to Companies Supporting U.S. National Interests | FDA MindMed already has Breakthrough status for MM-120 and that status would have not been granted if there was not a combination of the follow: delivering innovative medicines addressing a health crisis unmet public health needs increasing domestic drug manufacturing So, I would find it hard to believe they don't get one of these vouchers.... "The FDA's new Commissioner’s National Priority Voucher (CNPV) program, set to begin in 2025, aims to significantly reduce the review time for drug approvals from 10-12 months to just one to two months*. This program will allow drug developers to participate in a novel priority pathway, enhancing communication and providing accelerated approval if applicable legal requirements are met. The program will be limited to companies aligned with U.S. national priorities, and* it will incorporate elements from existing priority review programs" 1-2 month approval time lines! Will include "other" review programs - BTD Very very bullish.
FAQs: Commissioner’s National Priority Voucher Program FAQs: Commissioner’s National Priority Voucher Program | FDA Q4: Are CNPVs transferrable to another company? A4: These vouchers are non-transferrable. However, they will remain valid through changes in company ownership. Will allow a company that could potentially buy them out to continue the process is how I read that for any of these companies. Q5: Does the CNPV program affect pre-existing expedited review programs, such as fast track designation, breakthrough therapy designation, accelerated approval, and priority review designation? A5: No, the CNPV program will not affect other programs but will incorporate some of their elements. Smoother running process as a whole. Q7. Do the CNPVs expire? A7: Yes, the voucher must be used within two years following receipt from the FDA. Right around the corner Q8: What type of drugs are candidates for the CNPV designation? A8: The program can be applied to drugs in any area of medicine. The program does not currently apply to devices or combination drug-device applications. MNMD is supported
Wells Fargo Biotech Aquisition Target Heatmap with possible matches. MNMD listed in report as strong acquisition target for Biogen and others.
RFK Says Trump Administration Could Provide Psychedelic Therapy To Military Veterans ‘Within 12 Months’ https://www.marijuanamoment.net/rfk...herapy-to-military-veterans-within-12-months/
